BR112018068261A2 - microorganismo comensal transitório para melhorar a saúde do intestino - Google Patents

microorganismo comensal transitório para melhorar a saúde do intestino

Info

Publication number
BR112018068261A2
BR112018068261A2 BR112018068261A BR112018068261A BR112018068261A2 BR 112018068261 A2 BR112018068261 A2 BR 112018068261A2 BR 112018068261 A BR112018068261 A BR 112018068261A BR 112018068261 A BR112018068261 A BR 112018068261A BR 112018068261 A2 BR112018068261 A2 BR 112018068261A2
Authority
BR
Brazil
Prior art keywords
transient
bowel health
commensal microorganism
improve bowel
commensal
Prior art date
Application number
BR112018068261A
Other languages
English (en)
Inventor
Kyle David
FREEMAN-SHARKEY Samara
Frese Steven
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of BR112018068261A2 publication Critical patent/BR112018068261A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção aqui descrita refere-se, de modo geral, a administração de compostos para promover cicatrização de mucosa em mamíferos em necessidade dos mesmos, mas não limitado a humanos. os compostos podem incluir bifidobactéria e oligossacarídeos de leite de mamíferos.
BR112018068261A 2016-03-11 2017-03-13 microorganismo comensal transitório para melhorar a saúde do intestino BR112018068261A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307420P 2016-03-11 2016-03-11
PCT/US2017/022209 WO2017156550A1 (en) 2016-03-11 2017-03-13 A transient commensal microorganism for improving gut health

Publications (1)

Publication Number Publication Date
BR112018068261A2 true BR112018068261A2 (pt) 2019-01-15

Family

ID=59789754

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068261A BR112018068261A2 (pt) 2016-03-11 2017-03-13 microorganismo comensal transitório para melhorar a saúde do intestino

Country Status (8)

Country Link
US (1) US20200046782A1 (pt)
EP (1) EP3426270A4 (pt)
CN (1) CN109414464A (pt)
AU (2) AU2017230187A1 (pt)
BR (1) BR112018068261A2 (pt)
CA (1) CA3017357A1 (pt)
SG (1) SG11201807809XA (pt)
WO (1) WO2017156550A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ611807A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
BR112014004772A2 (pt) 2011-08-29 2017-03-21 Abbott Lab oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
EP3722412A4 (en) * 2017-12-08 2021-11-17 Morinaga Milk Industry Co., Ltd. NEW BIFIDOBACTERIUM, AND COMPOSITION CONTAINING THIS BACTERIA
CN109481476B (zh) * 2018-12-29 2021-09-07 重庆第二师范学院 发酵乳杆菌cqpc04在制备食品或改善溃疡性结肠炎的药品中的应用
CN114728028A (zh) * 2019-04-17 2022-07-08 纽泰克温图斯公司 包括具有增强的持久性的新微生物的组合物、新微生物和益生元的协同组合
BR112022005578A2 (pt) * 2019-09-24 2022-09-20 Prolacta Bioscience Inc Composições e métodos para tratamento de doenças inflamatórias e imunes
EP4034145A4 (en) * 2019-09-24 2023-10-11 The Regents of the University of California BENEFICIAL BACTERIA AND SECRETORY IMMUNOGLOBULIN A
JP7516053B2 (ja) * 2020-01-20 2024-07-16 森永乳業株式会社 組成物並びに飲食品組成物、栄養組成物および調製乳
WO2022011157A1 (en) * 2020-07-08 2022-01-13 Glycosyn LLC Use of 2'-fl for treatment of symptoms associated with autism spectrum disorder
CN116322371A (zh) * 2020-08-14 2023-06-23 普罗莱克塔生物科学公司 与细菌疗法一起使用的人乳寡糖组合物
AU2021332150A1 (en) * 2020-08-24 2023-03-23 Intrinsic Medicine, Inc. Immunomodulatory oligosaccharides for the treatment of autism spectrum disorder
CN114431484A (zh) * 2020-11-06 2022-05-06 内蒙古伊利实业集团股份有限公司 人乳寡糖在提高肠道对沙门氏菌感染抵御能力中的应用
KR20230131228A (ko) * 2021-01-12 2023-09-12 프롤랙타 바이오사이언스, 인코포레이티드 신바이오틱 치료 요법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571158A (en) * 2006-03-10 2011-08-26 Nutricia Nv Use of non-digestible saccharides administered to a pregnant woman for giving an infant the best start after birth
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP3369739A1 (en) * 2010-07-12 2018-09-05 The Regents of The University of California Bovine milk oligosaccharides
NZ612386A (en) * 2010-12-31 2015-02-27 Abbott Lab Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
US9567361B2 (en) * 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
MX2016006060A (es) * 2013-11-15 2016-08-03 Nestec Sa Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños.
CN107249611A (zh) * 2014-10-24 2017-10-13 进化生物系统股份有限公司 活化的双歧杆菌及其应用方法

Also Published As

Publication number Publication date
US20200046782A1 (en) 2020-02-13
EP3426270A4 (en) 2020-04-01
EP3426270A1 (en) 2019-01-16
CN109414464A (zh) 2019-03-01
SG11201807809XA (en) 2018-10-30
WO2017156550A1 (en) 2017-09-14
AU2024203621A1 (en) 2024-06-20
AU2017230187A1 (en) 2018-10-04
CA3017357A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
BR112018068261A2 (pt) microorganismo comensal transitório para melhorar a saúde do intestino
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
BR112017018656A2 (pt) bactéria modificada para tratar doenças que se beneficiam a partir de inflamação intestinal reduzida e/ou fortalecimento da barreira mucosa intestinal
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2019010907A (es) Agonistas del receptor x farnesoide, y usos de los mismos.
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2018013504A (es) Metodos de fabricacion, composiciones y aplicaciones medicas de productos farmaceuticos de cannabis administrables oralmente.
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112018012873A2 (pt) vacina de vírus zika
EA201990043A1 (ru) Антибактериальные соединения
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
BR112018069023A2 (pt) métodos de tratamento de doenças colestáticas
BR112015021888A2 (pt) inibidores de dna-ik
BR112015002755A8 (pt) Derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico e uso de derivados
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112017014345A2 (pt) populações de células do rpe e métodos de gerar as mesmas
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INFINANT HEALTH, INC. (US)

B25G Requested change of headquarter approved

Owner name: INFINANT HEALTH, INC. (US)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024010999-9 PROTOCOLO 870240046294 EM 31/05/2024 17:04.

B09B Patent application refused [chapter 9.2 patent gazette]